Phase 1 Study of Evalstotug (BA3071), an anti–CTLA-4 Conditionally Active Biologic, in Combination with Nivolumab in Advanced Solid Tumors
Development of A Humanized Anti-IL-22 Antibody for Cancer and Inflammation Therapy
Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches
